Source Paper
Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla.
D Marples, S Christensen, E I Christensen, P D Ottosen, S Nielsen
Journal of Clinical Investigation • 1995
Source Paper
D Marples, S Christensen, E I Christensen, P D Ottosen, S Nielsen
Journal of Clinical Investigation • 1995
Lithium, a widely used treatment for bipolar affective disorders, often causes nephrogenic diabetes insipidus. The effect of chronic lithium therapy on the expression of the vasopressin-regulated water channel Aquaporin-2 (AQP2) in rat kidney was examined. Membranes were prepared from inner medulla of one kidney from each rat, while the contralateral one was fixed for immunofluorescence and immunoelectronmicroscopy. Immunoblotting revealed that lithium treatment reduced AQP2 expression dramatically, to 31 +/- 8% after 10 d and to 4 +/- 1% after 25 d, coincident with development of severe polyuria. Immunofluorescence and immunogold quantitation confirmed the lithium-induced decrease in AQP2 expression (from 11.2 +/- 1.0 to 1.1 +/- 0.2 particles/microns 2). The downregulation was only partly reversed by return to lithium-free diet for 1 wk (40 +/- 8% of control). Furthermore, immunoblotting and immunogold quantitation revealed that 2 d of thirsting or 7 d of dDAVP treatment, in the continued presence of lithium, increased AQP2 expression by six- and threefold, respectively, coincident with increased urinary osmolality. Thirsting increased AQP2 immunolabeling mainly of vesicles, whereas dDAVP caused accumulation of AQP2 predominantly in the subapical region and plasma membrane. Thus, lithium causes marked downregulation of AQP2 expression, only partially reversed by cessation of therapy, thirsting or dDAVP treatment, consistent with clinical observations of slow recovery from lithium-induced urinary concentrating defects.
Objective: Examine the effect of chronic lithium therapy on aquaporin-2 (AQP2) water channel expression in rat kidney medulla and the development of polyuria
This is a Lithium Treatment Study protocol using rat as the model organism. The procedure involves 11 procedural steps, 4 equipment items, 2 materials. Extracted from a 1995 paper published in Journal of Clinical Investigation.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
~3.6 week study window
Core workflow
Initiate chronic lithium treatment • Harvest kidney tissue • Prepare kidney membranes
Primary readouts
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
Use the page like this
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Begin chronic lithium therapy in rats to induce nephrogenic diabetes insipidus and examine effects on AQP2 expression
Note: Two timepoints examined: 10 days and 25 days of lithium treatment
“The effect of chronic lithium therapy on the expression of the vasopressin-regulated water channel Aquaporin-2 (AQP2) in rat kidney was examined”
Collect both kidneys from each rat - one for membrane preparation and one for immunofluorescence and immunoelectronmicroscopy analysis
Note: Bilateral sampling allows for parallel analysis of protein expression and tissue localization
“Membranes were prepared from inner medulla of one kidney from each rat, while the contralateral one was fixed for immunofluorescence and immunoelectronmicroscopy”
Isolate membranes from the inner medulla of one kidney for immunoblotting analysis
Note: Specific to inner medulla region
“Membranes were prepared from inner medulla of one kidney from each rat”
Conduct immunoblotting analysis to measure AQP2 expression levels in kidney membranes at different timepoints
Note: Measurements taken at 10 days and 25 days of lithium treatment
“Immunoblotting revealed that lithium treatment reduced AQP2 expression dramatically, to 31 +/- 8% after 10 d and to 4 +/- 1% after 25 d”
Conduct immunofluorescence microscopy on fixed kidney tissue to visualize and confirm AQP2 expression changes
Note: Performed on contralateral kidney fixed tissue
“Immunofluorescence and immunogold quantitation confirmed the lithium-induced decrease in AQP2 expression (from 11.2 +/- 1.0 to 1.1 +/- 0.2 particles/microns 2)”
Conduct immunoelectronmicroscopy with immunogold quantitation to measure AQP2 particle density and subcellular localization
Note: Quantitative analysis of particle density per unit area
“Immunofluorescence and immunogold quantitation confirmed the lithium-induced decrease in AQP2 expression (from 11.2 +/- 1.0 to 1.1 +/- 0.2 particles/microns 2)”
Discontinue lithium treatment and return rats to lithium-free diet to examine reversibility of AQP2 downregulation
Note: Partial reversal of AQP2 downregulation observed
“The downregulation was only partly reversed by return to lithium-free diet for 1 wk (40 +/- 8% of control)”
Subject rats to 2 days of water deprivation while continuing lithium treatment to examine AQP2 expression changes
Note: Increased AQP2 expression primarily in vesicles
“2 d of thirsting or 7 d of dDAVP treatment, in the continued presence of lithium, increased AQP2 expression by six- and threefold, respectively”
Administer dDAVP (vasopressin analog) for 7 days while continuing lithium treatment to examine AQP2 expression and localization
Note: Caused accumulation of AQP2 predominantly in subapical region and plasma membrane
“7 d of dDAVP treatment, in the continued presence of lithium, increased AQP2 expression by threefold, respectively, coincident with increased urinary osmolality”
Assess urinary osmolality as a functional measure of kidney concentrating ability in response to treatments
Note: Increased urinary osmolality observed with thirsting and dDAVP treatment
“coincident with increased urinary osmolality”
Determine subcellular distribution of AQP2 protein in response to different treatments using immunofluorescence and immunoelectronmicroscopy
Note: Thirsting increased AQP2 mainly in vesicles; dDAVP caused accumulation in subapical region and plasma membrane
“Thirsting increased AQP2 immunolabeling mainly of vesicles, whereas dDAVP caused accumulation of AQP2 predominantly in the subapical region and plasma membrane”
This section explains what the experiment is doing, which readouts matter, what the data artifacts usually look like, and how the analysis should flow from raw capture to reported result.
Examine the effect of chronic lithium therapy on aquaporin-2 (AQP2) water channel expression in rat kidney medulla and the development of polyuria
Objective
Examine the effect of chronic lithium therapy on aquaporin-2 (AQP2) water channel expression in rat kidney medulla and the development of polyuria
Subjects
From paperrat • Not specified • unknown • Not specified • Not specified
Cohort notes
From paperBilateral kidney sampling performed - one kidney used for membrane preparation, contralateral kidney used for immunofluorescence and immunoelectronmicroscopy
Initiate chronic lithium treatment (10 days and 25 days treatment periods examined)
Harvest kidney tissue (Not specified)
Prepare kidney membranes (Not specified)
Perform immunoblotting (Not specified)
AQP2 protein expression levels (measured by immunoblotting as percentage of control)
From paperQuantitative analysis of immunoblotting results expressed as percentage of control; immunogold quantitation expressed as particles per micrometer squared; statistical measures reported as mean +/- standard error
Artifact type
Band images paired with densitometry summaries
Comparison focus
Compare normalized protein expression between experimental groups
AQP2 immunogold particle density (particles per micrometer squared)
From paperQuantitative analysis of immunoblotting results expressed as percentage of control; immunogold quantitation expressed as particles per micrometer squared; statistical measures reported as mean +/- standard error
Artifact type
Band images paired with densitometry summaries
Comparison focus
Compare normalized protein expression between experimental groups
Development and severity of polyuria
From paperQuantitative analysis of immunoblotting results expressed as percentage of control; immunogold quantitation expressed as particles per micrometer squared; statistical measures reported as mean +/- standard error
Artifact type
Band images paired with densitometry summaries
Comparison focus
Compare normalized protein expression between experimental groups
Urinary osmolality
From paperQuantitative analysis of immunoblotting results expressed as percentage of control; immunogold quantitation expressed as particles per micrometer squared; statistical measures reported as mean +/- standard error
Artifact type
Band images paired with densitometry summaries
Comparison focus
Compare normalized protein expression between experimental groups
AQP2 protein expression levels (measured by immunoblotting as percentage of control)
From paperRaw artifact
Membrane or gel image with visible bands for target and control proteins
Processed artifact
Band quantification and normalized densitometry values
Final reported form
Relative expression values or fold-change comparisons across groups
AQP2 immunogold particle density (particles per micrometer squared)
From paperRaw artifact
Membrane or gel image with visible bands for target and control proteins
Processed artifact
Band quantification and normalized densitometry values
Final reported form
Relative expression values or fold-change comparisons across groups
Development and severity of polyuria
From paperRaw artifact
Membrane or gel image with visible bands for target and control proteins
Processed artifact
Band quantification and normalized densitometry values
Final reported form
Relative expression values or fold-change comparisons across groups
Urinary osmolality
From paperRaw artifact
Membrane or gel image with visible bands for target and control proteins
Processed artifact
Band quantification and normalized densitometry values
Final reported form
Relative expression values or fold-change comparisons across groups
Acquisition
Capture matched images from the relevant tissue region using the same acquisition settings across samples.
Preprocessing / cleaning
Quantitative analysis of immunoblotting results expressed as percentage of control; immunogold quantitation expressed as particles per micrometer squared; statistical measures reported as mean +/- standard error
Scoring or quantification
Quantify the primary readouts for this experiment: AQP2 protein expression levels (measured by immunoblotting as percentage of control); AQP2 immunogold particle density (particles per micrometer squared); Development and severity of polyuria; Urinary osmolality.
Normalization
Normalize expression or signal values against the stated control or loading reference before comparing groups.
Statistical comparison
Statistical method not yet structured for this page.
Reporting output
Report representative outputs alongside summary comparisons for AQP2 protein expression levels (measured by immunoblotting as percentage of control), AQP2 immunogold particle density (particles per micrometer squared), Development and severity of polyuria, Urinary osmolality.
Source links and direct wording from the methods section for validation and deeper review.
Citation
D Marples et al. (1995). Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla.. Journal of Clinical Investigation
“”
“”
“”
“”
Direct vendor pages are linked from the protocol above. This section stays focused on the full comparison view and the prep checklist.
Gather these items before starting the experiment. Check off items as you prepare.
Not specified • Not specified • Not specified • Not mentioned
Not specified • Not specified • Not specified • Not mentioned
Not specified • Not specified • Not specified • Not mentioned
Not specified • Not specified • Not specified • Not mentioned
Not specified • Not specified • Not specified • Not mentioned
Not specified • Not specified • Not specified • Not mentioned
Use this section as the page quality checkpoint. It keeps section navigation, evidence access, readiness, and verification meaning in one place.
Current status surfaces were computed from experiment data updated Feb 28, 2026.
Source access
Jump back into the original paper or the methods evidence section when you need exact wording, exclusions, or method-specific caveats.
This protocol has structured steps plus evidence quotes, and is ready for canonical sync.
Steps
11
Evidence Quotes
17
Protocol Items
6
Linked Products
0
Canonical Sync
Pending
What this means
The completeness score reflects how much structured protocol data is present: steps, methods evidence, listed materials, linked products, and paper provenance.
Computed from the current experiment record updated Feb 28, 2026.
Canonical Sync shows whether a ConductGraph-backed protocol is available for this experiment route right now. It is a sync-status signal, not a claim that every downstream vendor link or step detail is perfect.
Steps
11
Evidence
17
Specific Products
0/0
Canonical Sync
Pending
What this score means
The verification score reflects evidence coverage, subject detail, paper provenance, step depth, and whether linked products resolve to specific item pages instead of generic searches.
Computed from the current experiment record updated Feb 28, 2026.
A page can have structured steps and still need review when evidence is thin, product links are generic, or canonical protocol coverage is still pending.
What still needs work